FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956029463> ?p ?o ?g. }

• W2956029463 abstract "Objectives: Studies in murine syngeneic tumors are critical in the development of immune-based therapies, yet there still are knowledge gaps in the functional meaning (vs. response and resistance to treatments) of baseline molecular and immunological features in these tumors. We developed a quantitative systems model of immuno-oncology (IO), to (i) understand factors within the TME which may underlie anti PD-(L)1 and CTLA-4 efficacy in 6 syngeneic tumors (4T1, LLC, CT-26, MC-38, B16, RENCA); (ii) identify potential baseline factors which relate to treatment resistance. Methods: Our IO model [1] was used, firstly to incorporate rich datasets from the 6 syngeneic tumor types [2] and to characterize differences in baseline TME conditions. The model was then used to perform mechanistic population simulations of the initiation and development of anti-tumor T cell immune responses, linked to observed individual animal- and cohort-level tumor size dynamics (TSD) under anti PD-(L)1 and CTLA-4 treatments. Variability in individual tumor size dynamics was taken into account using a mixed-effects technique, implemented in the model at the level of tumor-infiltrating T cell influx. Results: The model adequately described individual- and cohort-level TSD patterns, for all treatment regimens in all 6 tumor types. The model incorporated in one quantitative framework immune cell count data measured in these tumors, by capturing empirical dependencies between TME properties and model parameters. Anti PD-L1 therapy was incorporated into the model via a direct increase in an immune activation rate (IAR) function in TME, validating our previous results [1]. Interestingly, an optimal model incorporating anti CTLA-4 mechanism of action was one considering an indirect effect on IAR through the decrease of immuno-suppressive cell (ISC) function, which supports the hypothesis that the driving force of anti CTLA-4 effects in syngeneic tumors would go through ISC deactivation, e.g., via regulatory T cell (Tregs) depletion. Also, higher counts of Tregs at baseline (e.g., CT26, RENCA) correlated well with responses to anti CTLA-4 treatment. Higher levels of macrophages and/or MDSC infiltration in lesser “immunologically hot” tumors (e.g., 4T1, MC38, LLC) were shown to be the main immuno-suppressive factors limiting tumor responsiveness to checkpoint inhibitor treatments. Conclusions: This quantitative model may be used as a platform to analyze immune-based treatment data from various tumor types, while providing mechanistic insights on the contributions of baseline TME conditions to response or resistance to treatment. The model may be further used to perform predictive tumor response simulations (monotherapies and combinations), of untested anti CTLA-4, PD-(L)1 dose schedules and of other novel IO agents beyond these two checkpoint inhibitors. Citation Format: Gabriel Helmlinger, Ivan Azarov, Yuri Kosinsky, Veronika Voronova, Lulu Chu, Suzanne Mosely, Simon Dovedi, Kirill Peskov. Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1082." @default.
• W2956029463 created "2019-07-12" @default.
• W2956029463 creator A5006821234 @default.
• W2956029463 creator A5011295609 @default.
• W2956029463 creator A5023606392 @default.
• W2956029463 creator A5035224277 @default.
• W2956029463 creator A5050618782 @default.
• W2956029463 creator A5058809239 @default.
• W2956029463 creator A5062726882 @default.
• W2956029463 creator A5073399228 @default.
• W2956029463 date "2019-07-01" @default.
• W2956029463 modified "2023-09-25" @default.
• W2956029463 title "Abstract 1082: Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach" @default.
• W2956029463 doi "https://doi.org/10.1158/1538-7445.sabcs18-1082" @default.
• W2956029463 hasPublicationYear "2019" @default.
• W2956029463 type Work @default.
• W2956029463 sameAs 2956029463 @default.
• W2956029463 citedByCount "0" @default.
• W2956029463 crossrefType "proceedings-article" @default.
• W2956029463 hasAuthorship W2956029463A5006821234 @default.
• W2956029463 hasAuthorship W2956029463A5011295609 @default.
• W2956029463 hasAuthorship W2956029463A5023606392 @default.
• W2956029463 hasAuthorship W2956029463A5035224277 @default.
• W2956029463 hasAuthorship W2956029463A5050618782 @default.
• W2956029463 hasAuthorship W2956029463A5058809239 @default.
• W2956029463 hasAuthorship W2956029463A5062726882 @default.
• W2956029463 hasAuthorship W2956029463A5073399228 @default.
• W2956029463 hasBestOaLocation W29560294631 @default.
• W2956029463 hasConcept C143998085 @default.
• W2956029463 hasConcept C203014093 @default.
• W2956029463 hasConcept C2776107976 @default.
• W2956029463 hasConcept C2777701055 @default.
• W2956029463 hasConcept C2780851360 @default.
• W2956029463 hasConcept C2781053074 @default.
• W2956029463 hasConcept C2908647359 @default.
• W2956029463 hasConcept C502942594 @default.
• W2956029463 hasConcept C71924100 @default.
• W2956029463 hasConcept C8891405 @default.
• W2956029463 hasConcept C99454951 @default.
• W2956029463 hasConceptScore W2956029463C143998085 @default.
• W2956029463 hasConceptScore W2956029463C203014093 @default.
• W2956029463 hasConceptScore W2956029463C2776107976 @default.
• W2956029463 hasConceptScore W2956029463C2777701055 @default.
• W2956029463 hasConceptScore W2956029463C2780851360 @default.
• W2956029463 hasConceptScore W2956029463C2781053074 @default.
• W2956029463 hasConceptScore W2956029463C2908647359 @default.
• W2956029463 hasConceptScore W2956029463C502942594 @default.
• W2956029463 hasConceptScore W2956029463C71924100 @default.
• W2956029463 hasConceptScore W2956029463C8891405 @default.
• W2956029463 hasConceptScore W2956029463C99454951 @default.
• W2956029463 hasLocation W29560294631 @default.
• W2956029463 hasOpenAccess W2956029463 @default.
• W2956029463 hasPrimaryLocation W29560294631 @default.
• W2956029463 hasRelatedWork W2027065219 @default.
• W2956029463 hasRelatedWork W2042193380 @default.
• W2956029463 hasRelatedWork W2113906692 @default.
• W2956029463 hasRelatedWork W2402758010 @default.
• W2956029463 hasRelatedWork W2404306864 @default.
• W2956029463 hasRelatedWork W2493312559 @default.
• W2956029463 hasRelatedWork W2494023463 @default.
• W2956029463 hasRelatedWork W2592590860 @default.
• W2956029463 hasRelatedWork W2740654263 @default.
• W2956029463 hasRelatedWork W2741721751 @default.
• W2956029463 hasRelatedWork W2742138903 @default.
• W2956029463 hasRelatedWork W2772846324 @default.
• W2956029463 hasRelatedWork W2790244152 @default.
• W2956029463 hasRelatedWork W2885245392 @default.
• W2956029463 hasRelatedWork W2886582151 @default.
• W2956029463 hasRelatedWork W2887100182 @default.
• W2956029463 hasRelatedWork W2914412749 @default.
• W2956029463 hasRelatedWork W2990215545 @default.
• W2956029463 hasRelatedWork W3009279461 @default.
• W2956029463 hasRelatedWork W3170462408 @default.
• W2956029463 isParatext "false" @default.
• W2956029463 isRetracted "false" @default.
• W2956029463 magId "2956029463" @default.
• W2956029463 workType "article" @default.